{"id":435139,"date":"2024-10-20T07:47:57","date_gmt":"2024-10-20T07:47:57","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bs-en-iso-16638-22022-tc\/"},"modified":"2024-10-26T14:46:59","modified_gmt":"2024-10-26T14:46:59","slug":"bs-en-iso-16638-22022-tc","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bs-en-iso-16638-22022-tc\/","title":{"rendered":"BS EN ISO 16638-2:2022 – TC"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | 30466655 <\/td>\n<\/tr>\n | ||||||
47<\/td>\n | A-30432927 <\/td>\n<\/tr>\n | ||||||
48<\/td>\n | undefined <\/td>\n<\/tr>\n | ||||||
50<\/td>\n | European foreword Endorsement notice <\/td>\n<\/tr>\n | ||||||
51<\/td>\n | \u200b Annex G (informative) A-deviations <\/td>\n<\/tr>\n | ||||||
52<\/td>\n | Blank Page <\/td>\n<\/tr>\n | ||||||
54<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
55<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
57<\/td>\n | 1 Scope <\/td>\n<\/tr>\n | ||||||
58<\/td>\n | 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
60<\/td>\n | 4 Symbols and abbreviated terms 4.1 Symbols <\/td>\n<\/tr>\n | ||||||
61<\/td>\n | 4.2 Abbreviated terms 5 Purpose and need for monitoring programmes <\/td>\n<\/tr>\n | ||||||
63<\/td>\n | 6 General aspects <\/td>\n<\/tr>\n | ||||||
64<\/td>\n | 7 Special monitoring programmes 8 Task-related monitoring programmes for individual monitoring 9 Reference values as performance criteria for laboratories <\/td>\n<\/tr>\n | ||||||
65<\/td>\n | 10 Quality assurance and quality control for bioassay laboratories <\/td>\n<\/tr>\n | ||||||
66<\/td>\n | 11 Procedure for the assessment of exposures 11.1 \u200bAssessment of individual monitoring data 11.2 Properties of a software tool <\/td>\n<\/tr>\n | ||||||
67<\/td>\n | 11.3 Uncertainties 11.4 Quality assurance of the assessment process <\/td>\n<\/tr>\n | ||||||
68<\/td>\n | 12 Reporting and documentation 12.1 Reporting results for in vitro measurements 12.2 Documentation of the dose assessment <\/td>\n<\/tr>\n | ||||||
70<\/td>\n | Annex A (informative) Nuclear data of U-238 and U-235 decay <\/td>\n<\/tr>\n | ||||||
71<\/td>\n | Annex B (informative) Default classification of uranium compounds <\/td>\n<\/tr>\n | ||||||
72<\/td>\n | Annex C (informative) Measurement techniques for uranium in case of ingestion <\/td>\n<\/tr>\n | ||||||
75<\/td>\n | Annex D (informative) Excretion rates for ingestion of uranium compounds <\/td>\n<\/tr>\n | ||||||
77<\/td>\n | Annex E (informative) Committed effective dose per unit intake after ingestion of uranium compounds <\/td>\n<\/tr>\n | ||||||
78<\/td>\n | Annex F (informative) Estimation of uncertainties for internal dose assessments after ingestion <\/td>\n<\/tr>\n | ||||||
81<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Tracked Changes. Radiological protection. Monitoring and internal dosimetry for specific materials – Ingestion of uranium compounds<\/b><\/p>\n |